Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH12016 plus novel hormonal therapy in advanced prostate cancer
CTR20253297Phase 2Terminated
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLH12016 in prostate adenocarcinoma, sponsored by Qilu Pharmaceutical. Started Aug 2025; status: terminated.
02
Drugs
QLH12016
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20253297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253297.